Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.

Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.

Abstract: Prophylaxis or treatment of allergic airway inflammatory activity is described using Bifidobacterium longum NCIMB 41003. Also described is an exopolysaccharide which comprises the structure Formula (I). The polysaccharide may be used for treating or preventing undesirable inflammatory activity.

Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Bifidobacteria.

Abstract: Methods of use in humans of probiotic bacteria of the genus Bifidobacteria for regulating the condition of human keratinous tissue to achieve cosmetic beauty benefits. Said methods include regulation, either prophylactic or therapeutic, of the cosmetic appearance of human keratinous tissue, such as human hair, skin (e.g., scalp), and nails. In another aspect, the invention provides a method of marketing a composition comprising probiotic Bifidobacteria. In one embodiment, the method comprises: (1) offering for sale a composition comprising probiotic Bifidobacteria; and (2) communicating to a potential consumer of said composition that oral administration of said composition can regulate the condition of human keratinous tissue.

Abstract: Probiotic Bifidobacterium strain AH1205 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity such as undesirable gastrointestinal inflammatory activity for example inflammatory bowel disease.

Abstract: Probiotic Bifidobacterium strain AH1205 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity such as undesirable gastrointestinal inflammatory activity for example inflammatory bowel disease.

Abstract: An isolated polysaccharide has the structure [-?(1,3)-D-GaIpNAc-?(1,4)-D-Glcp-]n. The polysaccharide may be from a Bifidobacterium strain NCIMB 41003. The polysaccharide exhibits immunomodulatory activity.

Abstract: An isolated polysaccharide has the structure [-?(1,3)-D-GalpNAc-?(1,4)-D-Glcp-]n The polysaccharide may be from a Bifidobacterium strain NCIMB41003. The polysaccharide exhibits immunomodulatory activity.

Abstract: Bifidobacterium strain AH1206 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity for example undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease.

Abstract: The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.

Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.